PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25447049-8 2015 Further, inhibition of Src kinase activity using caveolin-1 scaffolding domain peptide suppressed bleomycin-, transforming growth factor beta-, or passive cigarette smoke-induced EMT and restored uPA expression while suppressing PAI-1. Bleomycin 98-107 caveolin 1, caveolae protein Mus musculus 49-59 30253845-8 2018 Lung transduction of adenovirus expressing p53 reduced bleomycin-induced PF in wild-type or caveolin-1-deficient mice. Bleomycin 55-64 caveolin 1, caveolae protein Mus musculus 92-102 28420992-9 2017 In SSc patients, healthy AA, and mice treated systemically with bleomycin, adipocytes lose caveolin-1 and PPARgamma and the subcutaneous adipose layer is diminished. Bleomycin 64-73 caveolin 1, caveolae protein Mus musculus 91-101 31873099-3 2019 We show that Cav-1 expression was downregulated both in alveolar epithelial type I cells in bleomycin-injured mouse lungs and in lung sections from IPF patients. Bleomycin 92-101 caveolin 1, caveolae protein Mus musculus 13-18 31873099-6 2019 Overexpression of Cav-1 suppressed bleomycin- or silica-induced activation of caspase-1 and maturation of pro-IL-1beta to secrete cleaved IL-1beta both in mouse lungs and in primary type I cells. Bleomycin 35-44 caveolin 1, caveolae protein Mus musculus 18-23 31826982-4 2019 Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice. Bleomycin 186-195 caveolin 1, caveolae protein Mus musculus 12-22 31826982-4 2019 Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice. Bleomycin 186-195 caveolin 1, caveolae protein Mus musculus 81-85 31826982-4 2019 Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice. Bleomycin 197-200 caveolin 1, caveolae protein Mus musculus 12-22 31826982-4 2019 Full-length caveolin-1 scaffolding domain peptide (CSP; amino acids 82 to 101 of Cav1: DGIWKASFTTFTVTKYWFYR) inhibits AEC apoptosis and fLf activation and expansion and attenuates PF in bleomycin (BLM)-induced lung injury in mice. Bleomycin 197-200 caveolin 1, caveolae protein Mus musculus 81-85 24067367-12 2013 Since Cav-1(-/-) mice also lack Cav-2 expression and show a different outcome after bleomycin treatment, we conclude that Cav-1 and Cav-2 have distinct roles in bleomycin induced-lung fibrosis, and that the balance of both proteins determines the development of the fibrotic process. Bleomycin 161-170 caveolin 1, caveolae protein Mus musculus 122-127 23042199-0 2012 Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. Bleomycin 26-35 caveolin 1, caveolae protein Mus musculus 102-112 20410070-2 2010 This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and patients with scleroderma and to examine the consequences of this deficiency and its reversal. Bleomycin 90-99 caveolin 1, caveolae protein Mus musculus 47-57 22362388-6 2012 The apparent protective effect against bleomycin-induced fibrosis in cav-1(-/-) mice was attributed to reduce cellular senescence and apoptosis in cav-1(-/-) epithelial cells during the early phase of lung injury. Bleomycin 39-48 caveolin 1, caveolae protein Mus musculus 69-74 22362388-6 2012 The apparent protective effect against bleomycin-induced fibrosis in cav-1(-/-) mice was attributed to reduce cellular senescence and apoptosis in cav-1(-/-) epithelial cells during the early phase of lung injury. Bleomycin 39-48 caveolin 1, caveolae protein Mus musculus 147-152 22362388-7 2012 Reduced matrix metalloproteinase (MMP)-2 and MMP-9 expressions indicated a low profile of senescence-associated secretory phenotype (SASP) in the bleomycin-injured cav-1(-/-) mice. Bleomycin 146-155 caveolin 1, caveolae protein Mus musculus 164-169 22362388-8 2012 However, IL-6 and macrophage inflammatory protein 2 were increased in WT and cav-1(-/-) mice after bleomycin challenge, suggesting that bleomycin-induced inflammatory response substantiated the SASP pool. Bleomycin 99-108 caveolin 1, caveolae protein Mus musculus 77-82 22362388-8 2012 However, IL-6 and macrophage inflammatory protein 2 were increased in WT and cav-1(-/-) mice after bleomycin challenge, suggesting that bleomycin-induced inflammatory response substantiated the SASP pool. Bleomycin 136-145 caveolin 1, caveolae protein Mus musculus 77-82 22362388-9 2012 Thus, loss of cav-1 attenuates early injury response to bleomycin by limiting stress-induced cellular senescence/apoptosis in epithelial cells. Bleomycin 56-65 caveolin 1, caveolae protein Mus musculus 14-19 20410070-8 2010 In bleomycin-treated mice, caveolin-1 expression was diminished in monocytes and CSD peptide inhibited leucocyte recruitment into the lungs. Bleomycin 3-12 caveolin 1, caveolae protein Mus musculus 27-37 18949888-8 2008 Systemic administration of penetratin-caveolin-1 peptide to mice with bleomycin-induced lung fibrosis reduced fibrosis. Bleomycin 70-79 caveolin 1, caveolae protein Mus musculus 38-48 17478448-3 2007 The present study evaluates the expression of caveolin-1, especially in bronchiolization, in C57BL/6J mice with bleomycin-induced lung fibrosis and in various types of re-epithelialization in human interstitial pneumonias (IPs). Bleomycin 112-121 caveolin 1, caveolae protein Mus musculus 46-56 17478448-4 2007 Immunohistochemically, levels of caveolin-1 decreased in the bronchiolar epithelium of mice treated with bleomycin. Bleomycin 105-114 caveolin 1, caveolae protein Mus musculus 33-43 35213624-1 2022 The caveolin-1 scaffolding domain (CSD, amino acids 82-101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis. Bleomycin 101-110 caveolin 1, caveolae protein Mus musculus 4-14 35213624-1 2022 The caveolin-1 scaffolding domain (CSD, amino acids 82-101 of caveolin-1) has been shown to suppress bleomycin-induced lung and skin fibrosis and angiotensin II (AngII)-induced myocardial fibrosis. Bleomycin 101-110 caveolin 1, caveolae protein Mus musculus 62-72